Genomics: Applications in mechanism elucidation

Advanced Drug Delivery Reviews

Volumn 61, Issue 5, 2009, Pages 369-374

  Gresham, Venita ^a   McLeod, Howard L ^a  

^a University of North Carolina   (United States)

Author keywords

Drug discovery; Drug target; Genomics; Mechanism of action; Molecular interactions; Pharmacogenomics; Small molecule drugs

Indexed keywords

MOLECULAR INTERACTIONS; MOLECULAR STRUCTURE;

DRUG DISCOVERY; DRUG TARGETS; GENOMICS; MECHANISM OF ACTION; PHARMACOGENOMICS; SMALL-MOLECULE DRUGS;

DRUG INTERACTIONS;

ARTICLE; DRUG ACTIVITY; DRUG COST; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL;

EID: 65049086286     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.12.002     Document Type: Note

References (31)

1. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348 (2003) 538-549
2. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn Jr. W.D., Morse D., Abraham S., Rahman A., Liang C., Lostritto R., Baird A., and Pazdur R. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
4. Yamaguchi T., Yoshida T., Kurachi R., Kakegawa J., Hori Y., Nanayama T., Hayakawa K., Abe H., Takagi K., Matsuzaki Y., Koyama M., Yogosawa S., Sowa Y., Yamori T., Tajima N., and Sak T. Identification of JTP-70902, a p15-INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci. 98 (2007) 1809-1816
5. Yoshida M., Kabe Y., Wada T., Asai A., and Handa H. A new mechanism of 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one dihydrochloride (TAS-103) action discovered by target screening with drug-immobilized affinity beads. Mol. Pharmacol. 73 (2008) 987-994
6. Becker F., Murthi K., Smith C., Come J., Costa-Roldan N., Kaufmann C., Hanke U., Degenhart C., Baumann S., Wallner W., Huber A., Dedier S., Dill S., Kinsman D., Hediger M., Bockovich N., Meier-Ewert S., Kluge A.F., and Kley N. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. 11 (2004) 211-223
7. Sidhu S.S., Lowman H.B., Cunningham B.C., and Wells J.A. Phage display for selection of novel binding peptides. Methods Enzymol. 328 (2000) 333-363
8. Rodi D.J., Makowski L., and Kay B.K. One from column A and two from column B: the benefits of phage display in molecular-recognition studies. Curr. Opin. Chem. Biol. 6 (2002) 92-96
9. McPherson M., Yang Y., Hammond P.W., and Kreider B.L. Drug receptor identification from multiple tissues using cellular-derived mRNA display libraries. Chem. Biol. 9 (2002) 691-698
10. Liu R., Barrick J.E., Szostak J.W., and Roberts R.W. Optimized synthesis of RNA-protein fusions for in vitro protein selection. Methods Enzymol. 318 (2000) 268-293
11. Paull K.D., Shoemaker R.H., Hodes L., Monks A., Scudiero D.A., Rubinstein L., Plowman J., and Boyd M.R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl. Cancer. Inst. 81 (1989) 1088-1092
12. Zaharevitz D.W., Gussio R., Leost M., Senderowicz A.M., Lahusen T., Kunick C., Meijer L., and Sausville E.A. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59 (1999) 2566-2569
13. Lum P.Y., Armour C.D., Stepaniants S.B., Cavet G., Wolf M.K., Butler J.S., Hinshaw J.C., Garnier P., Prestwich G.D., Leonardson A., Garrett-Engele P., Rush C.M., Bard M., Schimmack G., Phillips J.W., Roberts C.J., and Shoemaker D.D. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116 (2004) 121-137
14. Parsons A.B., Lopez A., Givoni I.E., Williams D.E., Gray C.A., Porter J., Chua G., Sopko R., Brost R.L., Ho C.H., Wang J., Ketela T., Brenner C., Brill J.A., Fernandez G.E., Lorenz T.C., Payne G.S., Ishihara S., Ohya Y., Andrews B., Hughes T.R., Frey B.J., Graham T.R., Andersen R.J., and Boone C. Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. Cell 126 (2006) 611-625
15. Winzeler E.A., Shoemaker D.D., Astromoff A., Liang H., Anderson K., Andre B., Bangham R., Benito R., Boeke J.D., and Bussey H. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285 (1999) 901-906
16. Guo Y., Weller P., Farrell E., Cheung P., Fitch B., Clark D., Wu S.Y., Wang J., Liao G., Zhang Z., Allard J., Cheng J., Nguyen A., Jiang S., Shafer S., Usuka J., Masjedizadeh M., and Peltz G. In silico pharmacogenetics of warfarin metabolism. Nat. Biotechnol. 24 (2006) 531-536
17. Guo Y., Weller P., Allard J., Usuka J., Masjedizadeh M., Wu S.Y., Fitch B., Clark D., Clark J.D., Shafer S., Wang J., Liao G., and Peltz G. Understanding our drugs and our diseases. Proc. Am. Thorac. Soc. 3 (2006) 409-412
18. Liang D.Y., Liao G., Wang J., Usuka J., Guo Y.Y., Peltz G., and Clark J.D. A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104 (2006) 1054-1062
19. Dolan M.E., Newbold K.G., Nagasubramanian R., Wu X., Ratain M.J., Cook Jr. E.H., and Badner J.A. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 64 (2004) 4353-4356
20. Watters J.W., Kraja A., Meucci M.A., Province M.A., and McLeod H.L. Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11809-11814
21. Huang R.S., Duan S., Shukla S.J., Kistner E.O., Clark T.A., Chen T.X., Schweitzer A.C., Blume J.E., and Dolan M.E. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet. 81 (2007) 427-437
22. Huang R.S., Duan S., Bleibel W.K., Kistner E.O., Zhang W., Clark T.A., Chen T.X., Schweitzer A.C., Blume J.E., Cox N.J., and Dolan M.E. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 9758-9763
23. Huang R.S., Duan S., Kistner E.O., Bleibel W.K., Delaney S.M., Fackenthal D.L., Das S., and Dolan M.E. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res. 68 (2008) 3161-3168
24. Lee A.C., Shedden K., Rosania G.R., and Crippen G.M. Data mining the NCI60 to predict generalized cytotoxicity. J. Chem. Inf. Model. 48 (2008) 1379-1388
25. Uga H., Kuramori C., Ohta A., Tsuboi Y., Tanaka H., Hatakeyama M., Yamaguchi Y., Takahashi T., Kizaki M., and Handa H. A new mechanism of methotrexate action revealed by target screening with affinity beads. Mol. Pharmacol. 70 (2006) 1832-1839
26. Jin Y., Yu J., and Yu Y.G. Identification of hNopp140 as a binding partner for doxorubicin with a phage display cloning method. Chem. Biol. 9 (2002) 157-162
27. Huang J., Zhu H., Haggarty S.J., Spring D.R., Hwang H., Jin F., Snyder M., and Schreiber S.L. Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16594-16599
28. Kohlhagen G., Paull K.D., Cushman M., Nagafuji P., and Pommier Y. Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison. Mol. Pharmacol. 54 (1998) 50-58
29. Baetz K., McHardy L., Gable K., Tarling T., Reberioux D., Bryan J., Andersen R.J., Dunn T., Hieter P., and Roberge M. Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 4525-4530
30. Blower P.E., Yang C., Fligner M.A., Verducci J.S., Yu L., Richman S., and Weinstein J.N. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2 (2002) 259-271
31. Liao G., Wang J., Guo J., Allard J., Cheng J., Ng A., Shafer S., Puech A., McPherson J.D., Foernzler D., Peltz G., and Usuka J. In silico genetics: identification of a functional element regulating H2-Ealpha gene expression. Science 306 (2004) 690-695